Friday, 16 October 2026European Markets

GL EVENTS Stock Is 29% Up In The Last 21 Sessions

Loading stream...

(vianews) - shares of gl events (cac 40: glo.pa) jumped by a staggering 29.05% in 21 sessions from 17.28 € to 22.30 € at 22:58 est on thursday, following the last session's upward trend. cac 40 is jumping 0.96% to 7,188.36 €, after three consecutive sessions in a row of losses.

about gl events

gl events sa provides venues and offices for events. it operates in three divisions: gl events live, gl events exhibitions, and gl events venues. the gl events live division offers various business line specializations and services, including turnkey solutions, designing, consulting, and staging the events for corporate, institutional, and sports events. the gl events exhibitions division manages and coordinates a portfolio of trade shows and consumer fairs in the food, culture, textile, construction, leisure, housing, environment, and trade and distribution sectors. the gl events venues division manages a network of 50 venues that include convention centers, exhibition centers, concert halls, and multi-purpose facilities. the company was formerly known as générale location and changed its name to gl events sa in 2003. the company was founded in 1978 and is headquartered in lyon, france. gl events sa is a subsidiary of polygone sa.

earnings per share

as for profitability, gl events has a trailing twelve months eps of 2.13 €.

pe ratio

gl events has a trailing twelve months price to earnings ratio of 10.47. meaning, the purchaser of the share is investing 10.47 € for every euro of annual earnings.

volume

today's last reported volume for gl events is 25613 which is 21.53% above its average volume of 21074.

more news about gl events (glo.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com